uniQure N.V.
Status: Publicly traded
Direct answer
uniQure N.V. is publicly traded on NASDAQ under the ticker QURE.
uniQure N.V. operates as a specialized gene therapy company, dedicated to pioneering therapeutic solutions for individuals grappling with severe genetic and other debilitating illnesses. The firm's most advanced project, Etranacogene dezaparvovec (designated as AMT-061), is currently progressing through a crucial Phase III pivotal trial, known as HOPE-B, targeting the treatment of hemophilia B. In addition to its...
Can you invest in uniQure N.V.?
Yes. uniQure N.V. is publicly traded on NASDAQ under the ticker QURE.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for uniQure N.V.
Detailed equity research is provided by MarketSnap.